08/01/2013

Cambridge Biomedical provides Btk Target Site Occupancy Validation

Cambridge Biomedical provides Btk Target Site Occupancy Validation services for "Inhibition of Btk with CC-292 Provides Early Pharmacodynamic Assesment of Activity in Mice and Humans" study.  Link to PubMed Paper
  
Latest News   

 Subscribe to our blog

For existing clients & test results please contact 
Customer Service:617.456.0800
All rights reserved. Cambridge Biomedical, the Cambridge Biomedical logo, Science and Service, and Custom
Solutions for Life Sciences Companies are registered or unregistered trademarks of Cambridge Biomedical Inc.
|     Privacy Statement     | Terms of Use